Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

BACKGROUND: High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemistry (IHC...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalmers, Zachary R., Connelly, Caitlin F., Fabrizio, David, Gay, Laurie, Ali, Siraj M., Ennis, Riley, Schrock, Alexa, Campbell, Brittany, Shlien, Adam, Chmielecki, Juliann, Huang, Franklin, He, Yuting, Sun, James, Tabori, Uri, Kennedy, Mark, Lieber, Daniel S., Roels, Steven, White, Jared, Otto, Geoffrey A., Ross, Jeffrey S., Garraway, Levi, Miller, Vincent A., Stephens, Phillip J., Frampton, Garrett M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395719/
https://www.ncbi.nlm.nih.gov/pubmed/28420421
http://dx.doi.org/10.1186/s13073-017-0424-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395719/
https://www.ncbi.nlm.nih.gov/pubmed/28420421
http://dx.doi.org/10.1186/s13073-017-0424-2

Ejemplares similares